CATALYSTReuters • 15h ago
Surgery Partners to be taken private by Bon Secours affiliate in $5.7 billion dealReuters report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
Why SGRY Stock Traded Steady Today — RQD Quant Desk Flash
$23.21 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $23.17
Surgery Partners Inc. (SGRY) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $3.04B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SGRY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SGRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Surgery Partners Inc. (NASDAQ: SGRY) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $23.21 (0.00% 1D, market cap $3.04B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, SGRY ranks #113 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SGRY compare to NHC and BKD in the Health Care sector?
▼
Within the Health Care sector (Hospital/Nursing Management), SGRY carries a Roarable C+ (66/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 9.9%. By comparison, NHC (National HealthCare Corporation) holds a B grade (72/100 RQD, P/E 27.7x, ROIC 10.1%, cap $3.23B) and BKD (Brookdale Senior Living Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC 0.3%, cap $2.48B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SGRY?
▼
Per SGRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001638833), Surgery Partners Inc. generated $0 in revenue, -$77.9M in net income, and $195.6M in free cash flow against $8.12B in total assets and $1.90B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $23.17 (-0.19%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 4.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY • 56.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SGRY)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (66/100 Composite)
🔍 WHY SGRY SCORES 66/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (26% of score)
20D Institutional Volume Accumulation (±5.5% realized swing band)
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)
▼ #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)
Capital intensity & 0% operating margin leave 12 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$14.83+3.8% Next Q
58
Q2 (-2Q)Grade C$15.40+50.9% Next Q
61
Q3 (-1Q)Grade C+$23.24-0.1% Next Q
63
CurrentGrade C+$23.21+1.4% Hist 90D α
66
Trajectory: C (58) → C+ (66)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the SGRY Bull Thesis Could Fail
Even with a 66/100 (C+) score, SGRY faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.67) or 200D SMA ($14.74) invalidates the momentum regime and cuts Target Base ($24.05) toward Bear Floor ($18.76).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SGRY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SGRY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SGRY Stock Traded Steady Today — RQD Quant Desk Flash
Surgery Partners Inc. (SGRY) slipped 0.00% to $23.21, trading at 99% of its 52-week range ($11.41 – $23.37). Solid steady margins (10% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 99% of its 52-week range ($11.41 – $23.37) with RSI-14 at 86.2 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.5% around $23.21 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 0% gross margin and $195.6M annual free cash flow.
Live SGRY Headlines & Catalysts
CATALYSTYahoo Finance • 18h ago
Why Surgery Partners (SGRY) stock is trading up todayYahoo Finance report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
CATALYSTDealroom • 21h ago
Bon Secours nears $6B buyout of Surgery Partners, shares jump 21%Dealroom report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 1d ago
Bon Secours nears $6B takeover of Surgery Partners, FT reports (SGRY:NASDAQ)Seeking Alpha report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
CATALYSTThe Motley Fool • 1d ago
Stock Market Today, Oct. 26: Surgery Partners Skyrockets 48% on $5.7 Billion HealthSpan AcquisitionThe Motley Fool report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Surgery Partners (SGRY) Stock Could Be 17% Stretched As Buyout Scrutiny BuildsYahoo Finance report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 1d ago
Surgery Partners' Buyout Leaves Little To Be Had By Holding On (Downgrade) (NASDAQ:SGRY)Seeking Alpha report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Is Surgery Partners (SGRY) Cheap After a 65% Five Year Fall?Yahoo Finance report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 3d ago
1 high-flying stock for long-term investors and 2 we turn down“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during m
MARKET WIREYahoo • 4d ago
2 surging stocks to keep an eye on and 1 facing challengesThe stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (SGRY Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SGRY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +63.45%⚡ TESTING RESISTANCE
2026-11-03O $23.21H $23.21L $23.21C $23.21VOL 3.51M
RES: $23.78SUP: $12.92SMA50: $15.67SMA200: $14.74
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SGRY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
15.7%/yr Implied 5Y Growth
vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SGRY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SGRY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SGRY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SGRY)
Health Care Rank #113 of 1016
⚔️ NHC vs SGRY Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SGRY vs. NHC, BKD, MD, ARDT)
Industry: Hospital/Nursing Management (14 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Surgery Partners Inc. (SGRY) ranks #113 by composite RQD confidence (66/100, grade C+) and #206 by equity capitalization ($3.04B). Within this direct 5-issuer industry benchmark cohort, ARDT leads on earnings valuation at 12.8x trailing P/E, while MD leads on capital efficiency and profitability with 33.6% ROIC and — gross margin. MD currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with SGRY at 66/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SGRY
ACTIVE
Surgery Partners Inc. | C+ | 66/100 | — | — | 9.9% | 0.00% | $3.04B | Benchmark Subject |
| NHC National HealthCare Corporation | B | 72/100 | 27.7x | — | 10.1% | -2.84% | $3.23B | /nhc-vs-sgry → |
| BKD Brookdale Senior Living Inc. | E | 32/100 | — | 26.2% | 0.3% | +1.17% | $2.48B | /bkd-vs-sgry → |
| MD Pediatrix Medical Group Inc. | B+ | 77/100 | 14.3x | — | 33.6% | +2.19% | $2.33B | /md-vs-sgry → |
| ARDT Ardent Health Inc. | C+ | 69/100 | 12.8x | — | 10.5% | -2.19% | $1.70B | /ardt-vs-sgry → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001638833In its most recent audited fiscal period (FY2025, filed 2025-12-31), Surgery Partners Inc. (SGRY) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$77.9M, operating cash flow of $274.3M, and free cash flow of $195.6M (-6.7% YoY). On the balance sheet, SGRY closed FY2025 with $8.12B in total assets against $1.90B in total debt (Altman Z-Score: 0.67, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$77.9M | $274.3M | $195.6M | $8.12B | $1.90B |
| FY2024 (FY) | 2024-12-31 | $0 | -$168.1M | $300.1M | $209.7M | $7.89B | $1.85B |
| FY2023 (FY) | 2023-12-31 | $0 | -$11.9M | $293.8M | $293.8M | $1.67B | $391.1M |
3. SGRY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SGRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Surgery Partners Inc. (NASDAQ: SGRY) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $23.21 (0.00% 1D, market cap $3.04B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, SGRY ranks #113 in composite RQD confidence.
How does SGRY compare to NHC and BKD in the Health Care sector?
Within the Health Care sector (Hospital/Nursing Management), SGRY carries a Roarable C+ (66/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 9.9%. By comparison, NHC (National HealthCare Corporation) holds a B grade (72/100 RQD, P/E 27.7x, ROIC 10.1%, cap $3.23B) and BKD (Brookdale Senior Living Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC 0.3%, cap $2.48B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SGRY?
Per SGRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001638833), Surgery Partners Inc. generated $0 in revenue, -$77.9M in net income, and $195.6M in free cash flow against $8.12B in total assets and $1.90B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SGRY trading relative to its 50-day, 200-day, and 52-week technical levels?
SGRY last traded at $23.21 (0.00% on volume of 3,514,095 shares), positioning the stock +48.12% above its 50-day simple moving average ($15.67) and +57.46% above its 200-day simple moving average ($14.74). Across its 52-week range of $11.41 to $23.37, SGRY sits at the 98.7% percentile with a 14-day RSI of 86.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.5% ($21.93 to $24.49).
SGRY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SGRY stock moving today?
Why SGRY Stock Traded Steady Today — RQD Quant Desk Flash. Solid steady margins (10% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 66/100 (C+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SGRY — Surgery Partners Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:24:21Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, SGRY scores 66 out of 100 (letter grade C+; verdict: "Roarable Hold — Upper Neutral / Watch for Breakout"). The five pillars are:
- Fundamental Cash Engine (8 / 20): Per the Roarable RQD rating, this pillar reflects ROIC of 9.9% and an FCF yield of 6.44%. It is the weakest pillar relative to its maximum, which suggests the cash-generation case is only moderately supportive at the current valuation.
- Whale 13F Flow (17 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar, indicating that large holders' activity is a notable positive input to the overall score.
- Insider Conviction (16 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the second-strongest pillar.
- Macro Regime Fit (15 / 20): Per the Roarable RQD rating, this pillar reflects a beta of 0.99 and sector sensitivity. A beta near 1.0 implies the stock has historically moved roughly in line with the broader market.
- Forensic Balance Sheet (10 / 20): Per the Roarable RQD rating, this pillar reflects an Altman Z-Score of 0.67, a Piotroski F-Score of 8/9, and a Debt/Equity ratio of 0.96. The strong Piotroski reading is offset by a low Altman Z-Score, which the rating treats as a meaningful balance-sheet risk.
For a prospective investor, the score implies a neutral stance with conditions for upgrade. Strength in institutional and insider flow is counterbalanced by a weak cash-engine pillar and a stressed Altman reading. Valuation context from the market data: forward P/E of 22 and EV/EBITDA of 9.7, while EPS (TTM) is -0.6, so earnings-based valuation is not supported by trailing results. Upside drivers cited in the source data center on the recent takeover-related news flow; the rating itself does not assign a price target.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $389.5M | $-77.9M | N/A | $195.6M | $239.9M | $1900.0M |
| FY 2024 | $0.0M | $348.8M | $-168.1M | N/A | $209.7M | $269.5M | $1846.3M |
| FY 2023 | $0.0M | $328.0M | $-11.9M | N/A | $293.8M | N/A | $391.1M |
Per the SEC financials, operating income rose from $328.0M (FY 2023) to $389.5M (FY 2025), while net income was negative in each reported period. The operating margin is 45.8% and the net margin is -9.2% per the market data section; the gross margin is reported as 0%. Per the Roarable RQD rating, ROIC is 9.9%, the Altman Z-Score is 0.67, and the Piotroski F-Score is 8/9; the Debt/Equity ratio is 0.96. Reported debt rose from $391.1M (FY 2023) to $1900.0M (FY 2025) per the SEC financials.
Open Questions
- What are the terms, price per share, and expected timing of the reported Bon Secours transaction, and is it confirmed?
- What is the revenue figure, given that the financials report $0.0M revenue across all periods?
- What is the reason for the Altman Z-Score of 0.67 and the rise in reported debt from $391.1M to $1900.0M?
- Why is the P/E (TTM) unavailable while EPS (TTM) is -0.6?
- What drives the N/A EPS and the missing FY 2023 cash figure?
SGRY Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Surgery Partners Inc. (SGRY) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Reuters • 15h ago
Surgery Partners to be taken private by Bon Secours affiliate in $5.7 billion deal Reuters report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 18h ago
Why Surgery Partners (SGRY) stock is trading up today Yahoo Finance report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Dealroom • 21h ago
Bon Secours nears $6B buyout of Surgery Partners, shares jump 21% Dealroom report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 1d ago
Bon Secours nears $6B takeover of Surgery Partners, FT reports (SGRY:NASDAQ) Seeking Alpha report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST The Motley Fool • 1d ago
Stock Market Today, Oct. 26: Surgery Partners Skyrockets 48% on $5.7 Billion HealthSpan Acquisition The Motley Fool report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Surgery Partners (SGRY) Stock Could Be 17% Stretched As Buyout Scrutiny Builds Yahoo Finance report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 1d ago
Surgery Partners' Buyout Leaves Little To Be Had By Holding On (Downgrade) (NASDAQ:SGRY) Seeking Alpha report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Is Surgery Partners (SGRY) Cheap After a 65% Five Year Fall? Yahoo Finance report covering Surgery Partners Inc. (SGRY) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SGRY Bull vs. Bear Conversation Board — What's Your Call at $23.21?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SGRY 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $25.07 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is SGRY (C+ • RQD 66/100) a Buy at $23.21?
Welcome to the SGRY (Surgery Partners Inc.) Roar Pit. Current RQD Composite is 66/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Hospital/Nursing Management. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $17.87 (-23.0%)
Spot @ $23.21 Pump the brakes on SGRY — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on SGRY, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Surgery Partners Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $26.92 (+16.0%)
Spot @ $23.21 SGRY cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on SGRY, the market is fixating on short-term headline noise in Hospital/Nursing Management and ignoring the balance sheet and cash flow trajectory. At $23.21 (52-wk range $11.41 - $23.37), any beat on forward guidance forces shorts and underweight funds to chase.